MedTrace Logo

Ulipristal Acetate for Cervical Preparation

NCT03802149 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 13

Last updated 2020-07-01

No results posted yet for this study

Summary

This is a prospective cohort study exploring a broadened use of ulipristal acetate as a cervical preparation agent for second trimester surgical abortion. Specifically, this pilot study will test the feasibility of using ulipristal as a pharmacologic cervical preparation with adjunct misoprostol prior to surgical abortion.

Conditions

  • Termination of Pregnancy

Interventions

DRUG

Ulipristal Acetate

90mg Ulipristal Acetate 18-24-hours prior to dilation and evacuation

Sponsors & Collaborators

Principal Investigators

  • Principal Investigator, MD · Stanford University

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-04-16
Primary Completion
2020-04-02
Completion
2020-04-02
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03802149 on ClinicalTrials.gov